PCM
REVBW icon

Prelude Capital Management’s Revelation Biosciences Warrant REVBW Stock Holding History

Prelude Capital Management’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,755
Closed -$11K – 2205
2021
Q3 		$11K Buy
17,755
+722
+4% +$438 ﹤0.01% 1623
2021
Q2 		$11K Buy
+17,033
New +$10.2K ﹤0.01% 1592

Other funds holding REVBW

OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Prelude Capital Management's REVBW Position: Q4 2021 in Review

Prelude Capital Management sold out of Revelation Biosciences Warrant (REVBW) in Q4 2021, closing a stake of 17,755 shares — an estimated $11K sold.

Prelude Capital Management first reported a position in REVBW in Q2 2021 and held it in 2 quarters. The position peaked at $11K in Q3 2021. 20 funds tracked by Wall St. Rank hold REVBW as of Q4 2021.

  • Prelude Capital Management reported no remaining Revelation Biosciences Warrant position as of Q4 2021 after selling out during the quarter.
  • Prelude Capital Management sold 17,755 Revelation Biosciences Warrant shares in Q4 2021, an estimated $11K.
  • Prelude Capital Management first reported a position in Revelation Biosciences Warrant in Q2 2021 and held it in 2 quarters.
  • Prelude Capital Management's Revelation Biosciences Warrant position peaked at $11K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q4 2021.

Based on Prelude Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.